Canaccord analyst Whitney Ijem lowered the firm’s price target on Ultragenyx (RARE) to $128 from $136 and keeps a Buy rating on the shares. The firm said the 2Q25 earnings report delivered a top- and bottom line beat with continued global demand for the company’s commercial franchises; FY25 guidance and outlook for 2027 full year GAAP profitability reaffirmed.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx Pharmaceutical’s Promising Growth and Financial Outlook: Analyst Recommends Buy
- Ultragenyx Earnings Call: Clinical Wins Amid Financial Challenges
- Ultragenyx Pharmaceutical: Strong Q2 Results and Promising Future Justify Buy Rating
- Ultragenyx Reports Growth Amidst Strategic Advancements
- Ultragenyx reports Q2 EPS ($1.17), consensus ($1.32)